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ABSTRACT
Objective: We assessed persistence patterns with oral antidiabetes drug
(OAD) in patients newly dispensed with different OAD classes.
Methods: We conducted a population-based cohort study using Quebec
Health Insurance Board data. Patients aged 18 years or more newly
dispensed an OAD between January 1, 1998 and December 31, 2003 were
included in the study (n = 98,940). Persistence was deﬁned as consistently
reﬁlling a prescription for the initial OAD within three times the days’
supply of the preceding claim. For nonpersistent patients, a second course
of therapy was deﬁned as treatment initiation with any OAD after a ﬁrst
discontinuation. Patients were followed from treatment initiation up to
December 31, 2004, ineligibility for the drug plan or death, whichever
came ﬁrst, and treatment discontinuation or second course of treatment.
Cox regression models were used to compute adjusted hazards ratios
(AHR) of persistence and initiation of second courses of therapy.
Results: The probability of persisting with the initial OAD over a
12-month period was 65% and 56% for patients initiated on metformin
and sylfonylurea, respectively. Compared to metformin, the likelihood of
discontinuing the initial OAD over the study period was signiﬁcantly
higher for patients on sulphonylureas (AHR: 1.32; 95% CI 1.29–1.34).
Patients started on sulphonylureas were also less likely to start a second
course of therapy after a ﬁrst treatment discontinuation (AHR: 0.91; 95%
CI 0.89–0.93).
Conclusions: Compared to diabetic patients initiated on metformin, those
initiated on sulphonylureas displayed poorer persistence patterns.
Keywords: diabetes, discontinuation patterns, oral antidiabetes drugs,
persistence.
Introduction
Diabetes is a common chronic disease. According to the World
Health Organization [1], around 177 million people were suffer-
ing from diabetes in 2000, and this number should total at least
300 million by 2025. Diabetes is responsible for 9% of the total
worldwide mortality. Type 2 diabetes accounts for more than
90% of diabetes cases.
When diet and exercise have failed to achieve glycemic
control, then starting to take an antidiabetes medication is rec-
ommended [2]. First-line classes of medications include bigu-
anides (metformin), insulin secretagogues sulfonylureas
(gliclazide, glimepiride, glyburide) and nonsulfonylureas (nateg-
linide, repaglinide), thiazolinediones (TZDs) (pioglitazone,
rosiglitazone), and the alpha-glucosidase inhibitor, acarbose.
Medication persistence refers to the act of conforming to a
recommendation of continuing treatment for the prescribed
length of time [3]. Persistence with drug treatment is an impor-
tant factor in determining the success of long-term therapy. This
is of particular relevance in the treatment of diabetes given that
this condition is chronic and typically requires long-term com-
mitment to pharmacotherapeutic regimens to gain and maintain
glycemic control and, as a consequence, prevent complications
[4].
Although many studies [5–12] have examined persistence
with oral antidiabetes drug (OAD) regimens, they generally
suffer from some limitations. For example, in most studies
[8–10,12], the duration of follow-up was no more than 1 year
and none has actually described returns to any antidiabetes
therapy after a ﬁrst discontinuation. Moreover, persistence with
metformin has been compared to persistence with sulfonylureas
in only two of these studies [6,7]. As perceived side effects are
known to be associated with discontinuation of drug treatment
[13] and as metformin and sulfonylureas are associated with
different side effects, there is a need to compare these two classes
of drugs in terms of persistence. Also, initial therapy may have
been dictated by contraindications which also modulate the risk
of side effects.
Our study was designed to examine and characterize persis-
tence and discontinuation patterns in actual clinical practice in a
Canadian population-based setting, using patients who were pre-
scribed antihyperglycemic pharmacotherapy with metformin or a
sulfonylurea for the ﬁrst time.
Methods
Study Design and Data Sources
A retrospective population-based inception cohort study was
undertaken, utilizing the databases of the Quebec Health Insur-
ance Board (RAMQ) and the Quebec Registry of Hospitaliza-
tions. These databases include information on patient
demographics, and hospital and physician services pertaining to
all permanent residents of the province of Quebec (population
approximately 7 million). The RAMQ drug plan database con-
tains also information on prescription drugs for Quebec residents
who are not eligible to a private drug insurance plan, welfare
recipients, and people aged 65 years and over (3.2 million in
2003). The drug plan database is known to be accurate for
prescription claims [14].
Eligible for cohort entry were new users of antihyperglycemic
pharmacotherapy aged 18 years or over; newly dispensed OAD
between January 1, 1998 and December 31, 2003 (no OAD or
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insulin prescription claimed in the 12 months leading up to the
ﬁrst dispensing date) and initiating antihyperglycemic treatment
with one of the ﬁve major drug classes (ATC class code A10B),
i.e., metformin, insulin secretagogues sulfonylureas, insulin
secretagogues nonsulfonylureas, TZDs, and alpha-glucosidase
inhibitor. Patients who were not eligible to the Quebec’s drug
plan for the entire 365-day period before the OAD treatment
initiation date were excluded. Those who received more than one
OAD at treatment initiation were also excluded. We later
excluded patients initiated on insulin secretagogues nonsulfony-
lureas, TZDs, and on the alpha-glucosidase inhibitor, acarbose,
because few patients were initiated on these drugs and they likely
had different characteristics from those initiated on metformin or
on a sulfonylurea. Indeed in Quebec, reimbursement of insulin
secretagogues nonsulfonylureas and TZDs, as ﬁrst-line agents is
restricted to those patients with a contraindication to the use of
both metformin and a sulfonylurea, or to individuals with renal
failure, whereas acarbose is mostly used in combination with
other OADs.
Study subjects were followed from treatment initiation (index
date) until December 31, 2004, ineligibility to the drug plan or
death, whichever came ﬁrst.
Persistence Analysis
Persistence with initial therapy was deﬁned as continuously reﬁll-
ing a prescription for the initial single OAD within thrice the
days’ supply of the preceding claim, regardless of add-on OAD or
insulin. Hospital-days were excluded from the calculation of this
“permissible gap” requirement for treatment discontinuation as
there is no information available on drug use during hospital
stays. Discontinuation date was deﬁned as the date of the last
prescription reﬁll plus the number of days’ supply. For nonper-
sistent patients, a new course of therapy was deﬁned as treatment
initiation with any OAD after a ﬁrst treatment discontinuation.
For illustrative purposes, Figure 1 displays OAD use in a hypo-
thetical patient considered to have discontinued therapy after
210 days (ﬁrst 90-day period, i.e., 3 times the days’ supply
without prescriptions, excluding hospital-days, ends at day 210)
and started a new course of therapy after 330 days.
Patients who were dispensed an additional OAD before or at
the date of the initial OAD discontinuation were regarded as
having been switched to another OAD before discontinuation
and therefore were not considered in the calculation for subse-
quent new courses of therapy.
Length of time to a ﬁrst treatment discontinuation (days from
treatment initiation to discontinuation), and length of time to a
new course of therapy after initial treatment discontinuation
(days from ﬁrst discontinuation to new course of therapy with
any OAD) were computed and described by subcohorts, as
deﬁned by initial OAD. Patients were censored at study termi-
nation date if they were persistent with therapy throughout
follow-up, or when they became ineligible for the drug plan, or at
time of death, if applicable. Persistence was evaluated for up to
an 84-month period from the index date.
Statistical Analysis
Initial treatment patterns, patients’ characteristics at treatment
initiation, as well as discontinuation patterns were described and
signiﬁcance tests were carried out using chi-square tests for
proportions and analyses of variance for continuous variables.
Persistence data for each OAD subcohort was analyzed
longitudinally. Length of time from a ﬁrst OAD initiation to
discontinuation, and length of time from a ﬁrst OAD discontinu-
ation to a second new course of OAD were described using
Kaplan–Meier curves. Statistical signiﬁcance of the differences
between curves was assessed using the log-rank test. Cox regres-
sion analyses were conducted to compare the likelihood of treat-
ment discontinuation for the sulfonylureas subcohort to that of
the metformin subcohort over the 84-month study period, con-
trolling for age, sex, calendar year of treatment initiation, initial
prescriber’s specialty, hospitalization for diabetes in the year
before treatment initiation, comorbidity score measured as the
number of different prescribed medications claimed in the year
before treatment initiation [15], obesity (ICD-9 278.0), and
mental disorder (ICD-9 290-319, 331.XX). This therefore
allowed the proportion of subjects still on initial OAD therapy at
different points in time to be compared across the two initial
treatment groups. The likelihood of starting a new course of
therapy after treatment discontinuation was also compared
across initial treatment groups using Cox regression models
adjusting for age, sex, calendar year of treatment initiation,
hospitalization for diabetes, the number of different prescribed
medications claimed in the year before treatment initiation, for
obesity and mental disorder. The proportionality assumption for
the proportional hazards models was met. To test the sensitivity
of the “thrice the days’ supply” permissible gap for persistence,
we repeated the analysis using “twice the days’ supply” as a
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Figure 1 Measurement deﬁnition.
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criterion. Statistical analyses were performed using SAS, version
9.1 [16].
Results
A total of 98,940 patients aged 18 years or over were included in
the analysis (Fig. 2). Characteristics of the study population at
initial treatment are presented in Table 1. The average age at
OAD treatment initiation was 64.8 years. Patients were predomi-
nantly prescribed their ﬁrst OAD treatment by a general practi-
tioner and more than two-thirds received metformin as an initial
therapy. Glyburide was prescribed to 93% of patients who
received a sulfonyurea. A total of 31,244 patients initiated a
second course of treatment after a ﬁrst discontinuation. Their
characteristics are described in Table 2.
In Quebec, patients on long-term pharmacotherapy are gen-
erally given prescriptions for 30 days. Indeed, respectively,
86.2% and 87.8% of ﬁrst prescriptions of sulfonylureas and
metformin were supplied for duration of 30 days. For all pre-
scriptions including initial prescriptions and prescriptions for
second courses of treatment, the median days’ supply was 30
days for both metformin and sulfonylureas.
A total of 8964 patients were dispensed an additional OAD
before or at the date of the initial OAD discontinuation and were
therefore considered to have been switched to another OAD
before discontinuation. Although they were considered nonper-
sistent in using their initial OAD, in subsequent analyses they
were not regarded as patients eligible for a second new course of
treatment after a ﬁrst discontinuation. The selection of patients
for subcohorts analyses is presented in Figure 3. OADs received
as a second course of treatment after a ﬁrst treatment discontinu-
ation is presented in Table 3. A majority of patients received an
OAD from the same antidiabetes drug class as a second course of
treatment.
The probability of persisting with the initial use of metformin
went from a high 65% to a low 40% after 1 and 6 years,
respectively, whereas the probability of persisting with sulfony-
lurea varied between 56% and 28% during that same period of
time. Median time to ﬁrst discontinuation was 0.39 years for both
metformin (mean: 0.86) and sulfonylurea (mean: 0.97). Persis-
tence with initial therapy was deﬁned as continuously reﬁlling a
prescription for the initial single OAD within thrice the days’
supply of the preceding claim, regardless of add-on OAD initial
users. Of those who discontinued their initial OAD, the probabil-
ity of initiating a new course of therapy in the ﬁrst year after
discontinuation was around 60%. This proportion increased over
the years to reach over 80% after 6 years. For those who initiated
a second course of therapy, the probability of persisting with the
141,019
112,382
103,432 were dispensed an OAD in the 
365 days prior to the index date 
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Figure 2 Selection of the study population.
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OAD therapy was not higher than 50% after 1 year and decreased
over time (data not shown). Figures 4 and 5 show the Kaplan–
Meier curves displaying the probability of patients persisting in
using their initial OAD treatment over a 7-year period (Fig. 4),
and the probability of restarting OAD treatment during the
follow-up period among the 43,428 patients who had discon-
tinued their ﬁrst course of treatment (Fig. 5).
Adjusted hazard ratios of initial OAD discontinuation, and of
a new course of treatment after discontinuation are presented in
Table 4 and in Table 5, respectively. For the entire study period,
patients initiated on a sulfonylurea were 32% more likely to
discontinue their initial treatment than those initiated on met-
formin. On the other hand, when compared to patients initiated
on metformin, those initiated on sulphonylureas were 9% less
likely to initiate a second course of treatment after discontinua-
tion. These results were statistically signiﬁcant. Using a permis-
sible gap of two times the days’ supply as a criterion for deﬁning
persistence had little effect on hazard ratios estimates (data not
shown).
Among the covariates included in the models, men and
patients whose antidiabetes treatment was initiated in 2000 or
later as opposed to 1998 had a decrease hazard of discontinuing
their initial OAD (Table 4). By contrast, having a physician other
than a general practitioner for initial prescriber or suffering from
a mental disorder in the year before OAD initiation was related
to an increase in the hazard of discontinuation. On the other
hand, being initiated on OAD in 2002 or later as opposed to
1998, or having been hospitalized in the year before OAD ini-
tiation was associated with a decrease in the hazard of initiating
a new course of treatment after the discontinuation of the initial
OAD (Table 5). Similarly, having been hospitalized or suffered
from obesity or from a mental disorder in the year before OAD
initiation was also related to a decrease in the hazard on initiat-
ing a new course of treatment after the discontinuation of the
initial OAD.
Conclusions
We found that over the study period, patients initiated on met-
formin showed better persistence with their initial OAD than
those initiated on a sulphonylurea. They were also more likely to
return to treatment after discontinuation.
Persistence with metformin and sulfonylureas has been
described in previous studies. For instance, in a study published
in 2001, Boccuzzi et al. [6] observed that the proportion of
patients who had, over a 12-month period, continuously reﬁlled
a prescription for their initial OAD within 1.5 times the days’
supply of the previous ﬁll was 11.9% and 11.3% for patients
initiated on metformin and on a sulfonylurea, respectively. In
another study also published in 2001, Dailey et al. [7] observed
that 16% of patients who initiated an OAD treatment using
metformin had continuously reﬁlled a prescription of their initial
OAD within 1.5 times the days’ supply of the previous ﬁll after
1 year; this compared to 15% of those who did the same using a
sulfonylurea. In our study, the probability of persisting over a
12-month period with the initial OAD was much higher than in
these two studies, which may be explained by the shorter pre-
scription reﬁll grace period used in the two previously mentioned
Table 1 Characteristics of patients (n = 98,940) by class of initial oral antidiabetes drug (OAD)
Characteristics* Total Metformin
Insulin secretagogues
sulfonylureas P value†
Patients 98,940 (100) 67,764 (68.5) 31,176 (31.5)
Age at treatment initiation, mean (SD) 64.8 (13.0) 64.2 (13.1) 66.1 (12.9) <0.0001
Age in years <0.0001
18–44 8,099 (8.2) 5,912 (8.7) 2,187 (7.0)
45–64 32,577 (32.9) 23,258 (34.3) 9,319 (29.9)
65+ 58,264 (58.9) 38,594 (57.0) 19,670 (63.1)
Sex <0.0001
Female 50,904 (51.5) 35,820 (52.9) 15,084 (48.4)
Male 48,036 (48.5) 31,944 (47.1) 16,092 (51.6)
Year of treatment initiation <0.0001
1998 15,560 (15.7) 7,660 (11.3) 7,900 (25.4)
1999 15,798 (16.0) 8,989 (13.3) 6,809 (21.8)
2000 15,851 (16.0) 10,452 (15.4) 5,399 (17.3)
2001 16,456 (16.6) 11,987 (17.7) 4,469 (14.3)
2002 17,517 (17.7) 13,851 (20.4) 3,666 (11.8)
2003 17,758 (18.0) 14,825 (21.9) 2,933 (9.4)
Region <0.0001
Rural 20,645 (20.9) 14,735 (21.7) 5,910 (19.0)
Urban 78,067 (78.9) 52,893 (78.1) 25,174 (80.7)
Missing 228 (0.2) 136 (0.2) 92 (0.3)
Hospitalized for diabetes in the 365-day period
before treatment initiation
<0.0001
Yes 1,081 (1.1) 554 (0.8) 527 (1.7)
No 97,859 (98.9) 67,210 (99.2) 30,649 (98.3)
Number of different medications in the
year before OAD initiation (median = 5)
<0.0001
Median 50,571 (51.1) 34,086 (50.3) 16,485 (52.9)
>Median 48,369 (48.9) 33,678 (49.7) 14,691 (47.1)
Initial prescriber’s speciality (%) <0.0001
Endocrinologist 4,907 (5.0) 3,425 (5.1) 1,482 (4.7)
Internist 4,884 (4.9) 3,120 (4.6) 1,764 (5.7)
General practitioner 84,580 (85.5) 58,557 (86.4) 26,023 (83.5)
Others 4,306 (4.3) 2,467 (3.6) 1,839 (5.9)
Missing 263 (0.3) 195 (0.3) 68 (0.2)
*Otherwise indicated, values are numbers and proportions (in %).
†Overall test of signiﬁcance for the hypothesis that both treatment groups are similar.
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studies (150% of days’ supply) than in ours (300% of days’
supply) when deﬁning persistence.
We have observed that patients initiated on metformin are
more likely to persist in using their initial treatment than those
patients initiated on a sulfonylurea. This result cannot be com-
pared to the results reported by Boccuzzi et al. [6] andDailey et al.
[7], as the risk of persisting between those initiated on metformin
and those initiated on a sulfonylurea was not measured and
compared in these studies. On the other hand, Hertz et al. [10]
have studied the difference in persistence among individuals initi-
ated on different classes of OAD. They have reported that, com-
pared to patients initiated on a sulfonylurea, the hazard ratio of
biguanide discontinuation was not statistically different (0.97;
95% CI 0.89–1.06). This difference of result between our study
and the one by Hertz et al. [10] may be explained by variations in
the length of observation, the nature of the population studied,
and by differences inmethodology. For example, in theHertz et al.
[10] study, the duration of follow-up was only 12 months, and the
Table 2 Characteristics of patients (n = 31,244) who initiated a second course of treatment after a ﬁrst discontinuation by class of initial oral
antidiabetes drug
Characteristics* Total Metformin
Insulin secretagogues
sulfonylureas P-value†
Patients 31,244 (100) 19,849 (63.5) 11,395 (36.5)
Age at treatment initiation, mean (sd) 63.1 (13.4) 62.5 (13.6) 64.1 (12.9) <0.0001
Age in years <0.0001
18–44 3,305 (10.6) 2,286 (11.5) 1,019 (8.9)
45–64 11,114 (35.6) 7,290 (36.7) 3,824 (33.6)
65+ 16,825 (53.8) 10,273 (51.8) 6,552 (57.5)
Sex <0.0001
Female 15,844 (50.7) 10,536 (53.1) 5,308 (46.6)
Male 15,400 (49.3) 9,313 (46.9) 6,087 (53.4)
Year of treatment initiation <0.0001
1998 6,661 (21.3) 3,138 (15.8) 3,523 (30.9)
1999 6,202 (19.9) 3,472 (17.5) 2,730 (24.0)
2000 5,523 (17.7) 3,559 (17.9) 1,964 (17.2)
2001 5,037 (16.1) 3,508 (17.7) 1,529 (13.4)
2002 4,500 (14.4) 3,487 (17.6) 1,013 (8.9)
2003 3,321 (10.6) 2,685 (13.5) 636 (5.6)
Region <0.0001
Rural 6,068 (19.4) 4,012 (20.2) 2,056 (18.0)
Urban 25,094 (80.3) 15,788 (79.5) 9,306 (81.7)
Missing 82 (0.3) 49 (0.3) 33 (0.3)
Hospitalized for diabetes in the 365-day period prior to treatment initiation <0.0001
Yes 282 (0.9) 146 (0.7) 136 (1.2)
No 30,962 (99.1) 19,703 (99.3) 11,259 (98.8)
Number of different medications in the year prior to OAD initiation (median = 5) <0.0001
median 17,534 (56.1) 10,852 (54.7) 6,682 (58.6)
>median 13,710 (43.9) 8,997 (45.3) 4,713 (41.4)
Initial prescriber’s speciality (%) <0.0001
Endocrinologist 1,660 (5.3) 1,122 (5.7) 538 (4.7)
Internist 1,610 (5.2) 974 (4.9) 636 (5.6)
General practitioner 26,554 (85.0) 17,012 (85.7) 9,542 (83.7)
Others 1,338 (4.3) 689 (3.5) 649 (5.7)
Missing 82 (0.3) 52 (0.3) 30 (0.3)
*Otherwise indicated, values are numbers and proportions (in %).
†Overall test of signiﬁcance for the hypothesis that both treatment groups are similar.
Figure 3 Flow chart of patients’ selection for
subcohorts analysis.
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6090 selected patients were all aged less than 65 years. By con-
trast, our follow-up period was up to 84 months, and our popu-
lation was not only older (mean age of 65 years) but larger
(n = 98,940), thus furnishingmore power for detecting differences
in risk. Moreover, in the study by Hertz et al. [10], persistent
patients were those continuously reﬁlling a prescription for an
OAD within 1.25 times the days’ supply of the previous ﬁll. This
is a more stringent deﬁnition of persistence than the one we used.
Another interesting ﬁnding emerges from our study. A major-
ity of patients who discontinued OAD treatment returned to
treatment within 1 year. This result is consistent with earlier
studies on the use of antihypertensive drugs [17,18] and on
statins [19]. Similarly, not only does persistence with OAD vary
across drug classes but also patients originally initiated on sul-
fonylureas were less likely to initiate a second course of treatment
after discontinuation. This may be the consequence of drug-
Table 3 Oral antidiabetes drug (OAD) received by patients (n = 31,244) as a second course of treatment after a ﬁrst treatment discontinuation by OAD
prescribed at treatment initiation
Oral antidiabetes drug prescribed as a second course of treatment after a ﬁrst treatment discontinuation
Initial oral antidiabetes drug class* Total Acarbose Metformin
Secretagogue
sulfonylurea
Secretagogue
nonsulfonylurea Thiazolidinedione
Metformin 19,849 (100) 103 (5.2) 14,382 (74.7) 4,749 (23.9) 132 (6.7) 483 (0.02)
Secretagogue sulfonylurea 11,395 (100) 90 (7.9) 3,979 (34.9) 7,040 (61.8) 112 (9.8) 174 (1.5)
*Values are numbers and proportions (in %).
Log-rank test, P < 0.0001
0.00
0.25
0.50
0.75
1.00
Time (years)
0 1 2 3 4 5 6 7
Number at risk
Metformin        67,764        42,060         27,053         17,121        10,230        5,428           2,161      
Sulfonylurea    31,176        16,198         11,666           8,372          5,787        3,607           1,658
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Figure 4 Probability of persisting with oral
antidiabetes drug treatment according to initial
oral antidiabetes class. , metformin; ,
sulfonylurea.
Log-rank test, P < 0.0001
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Figure 5 Probability of initiating a new course of
any oral antidiabetes drug treatment after a ﬁrst
treatment discontinuation according to initial
oral antidiabetes class. , metformin; ,
sulfonylurea.
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induced hypoglycemia which is higher in patients started on
sulphonylureas compared to metformin [2]. Although this result
was statistically signiﬁcant, the difference in relative risk is low
(9%). The clinical relevance of this latter result is therefore
unclear. Moreover, it is worth noting that the choice of initial
treatment should be tailored to the individual patient [2]. As an
example, patients with type 2 diabetes are often obese. In that
case, clinicians may prefer to prescribe metformin because it has
been associated with weight loss. Nevertheless, metformin is
relatively contraindicated in patients with renal failure and those
with gastrointestinal disturbances may suffer from diarrhea when
exposed to this drug. On the other hand, sulphonylureas are
often used when glucose control is far from optimal and the
clinician feels that metformin would not be efﬁcient in achieving
optimal glucose control in drug-naive patients. Also, gliclazide
has been reported to be associated with less hypoglycemia
episode in elderly patients. Thus, the treatment is modulated
depending on patient characteristics in day-to-day practice.
Some covariates were related to discontinuation of the initial
OAD. For example, being a man and increasing age were both
negatively associated with discontinuation of the initial OAD.
Other researchers have reported a similar association for age
[5,10] and for sex [10]. It suggests that men and older individuals
are more likely to continue their initial OAD treatment over
time.
We have observed that having a general practitioner for pre-
scribing physician was associated with a lower likelihood of
treatment discontinuation. In the past, it has been reported that
individuals whose prescribing physician was a general practitio-
ner, as opposed to an endocrinologist, were less likely to discon-
tinue their initial treatment [5]. It might be assumed that patients
treated by an endocrinologist are more severely ill than the others
and consequently, they may receive a closer follow-up. These
patients might be more likely to experience a switch to another
antidiabetes drug than patients who have a general practitioner
as their initial prescribing physician.
Results should be considered in light of the study limitations,
principally those inherent in the use of administrative databases.
First, the analysis was based on pharmacy reﬁlls although reﬁll-
ing may not represent actual use of medications. Second, infor-
mation on many clinical or demographic characteristics is not
captured by the RAMQ databases which precluded our analysis
of their association with OAD discontinuation. Because of this
lack of clinical data, we were not able to assess whether discon-
tinuation is due to the failure to achieve glycemic control or to
other reasons. Moreover, it cannot be ruled out that differences in
persistence between individuals on metformin and those on sul-
fonylureas might be because of confounding by indication. We
have tried to minimize this bias by adjusting among other things
for mental disorder in the year before OAD initiation, a covariate
Table 4 Hazard ratios (HR) of initial treatment discontinuation among new users (n = 98,940) of oral antidiabetes drugs (OAD) according to the initial
antidiabetes drug and to other characteristics
Characteristic
Initial treatment discontinuation
Unadjusted
HR 95% CI
Adjusted
HR 95% CI
Yes
N = 52,098 (52.7%)
No
N = 46,842 (47.3%)
N (%) N (%)
Initial OAD
Metformin 32,871 (63.1) 34,893 (74.5) 1.00 1.00
Sulfonylurea 19,227 (36.9) 11,949 (25.5) 1.34 1.32, 1.37 1.32 1.29, 1.34
Age at OAD initiation, mean
(SD)
64.0 (13.9) 65.7 (11.9) 0.99 0.99, 0.99 0.99 0.99, 0.99
Sex
Female 27,313 (52.4) 23,591 (50.4) 1.00 1.00
Male 24,785 (47.6) 23,251 (49.6) 0.95 0.94, 0.97 0.94 0.92, 0.95
Calendar year of OAD initiation
1998 10,188 (19.6) 5,372 (11.5) 1.00 1.00
1999 9,822 (18.9) 5,976 (12.7) 0.96 0.93, 0.98 0.97 0.95, 1.00
2000 9,020 (17.3) 6,831 (14.6) 0.89 0.87, 0.92 0.93 0.91, 0.96
2001 8,460 (16.2) 7,996 (17.1) 0.83 0.81, 0.86 0.89 0.87, 0.92
2002 7,992 (15.3) 9,525 (20.3) 0.81 0.78, 0.83 0.88 0.85, 0.90
2003 6,616 (12.7) 11,142 (23.8) 0.75 0.73, 0.77 0.82 0.80, 0.85
Initial prescriber’s specialty
General practitioner 43,975 (84.4) 40,605 (86.7) 1.00 1.00
Endocrinologist 2,728 (5.2) 2,179 (4.6) 1.10 1.06, 1.14 1.08 1.03, 1.12
Internist 2,750 (5.3) 2,134 (4.6) 1.14 1.10, 1.19 1.13 1.09, 1.17
Others 2,504 (4.8) 1,802 (3.8) 1.27 1.22, 1.33 1.22 1.17, 1.27
Missing 141 (0.3) 122 (0.3) 1.17 0.99, 1.38 1.20 1.02, 1.41
Hospitalized for diabetes in the
365-day period before OAD
initiation
No 51,507 (98.9) 46,352 (99.0) 1.00 1.00
Yes 591 (1.1) 490 (1.0) 1.07 0.99, 1.16 0.99 0.91, 1.07
Number of different medications
in the year before OAD
initiation (median = 5)
Median 27,264 (52.3) 23,307 (49.8) 1.00 1.00
>Median 24,834 (47.7) 23,535 (50.2) 0.98 0.97, 1.00 1.00 0.98, 1.02
Obesity*
No 49,743 (95.5) 44,799 (95.6) 1.00 1.00
Yes 2,355 (4.5) 2,043 (4.4) 1.06 1.01, 1.10 1.02 0.98, 1.06
Mental disorder*
No 41,195 (79.1) 38,072 (81.3) 1.00 1.00
Yes 10,903 (20.9) 8,770 (18.7) 1.14 1.12, 1.17 1.12 1.09, 1.14
*Measured in the year before OAD initiation.
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which we found to be associated to a 12% increase in the risk of
discontinuing the initial OAD. Despite these limitations, our
study was designed to examine and characterize persistence with
OAD in the actual clinical practice. It provides a population-
based description of long-term OAD taking.
To the best of our knowledge, this is the ﬁrst study to have
examined OAD treatment persistence and discontinuation pat-
terns longitudinally; yet such patterns have been studied with
antihypertensive [17,18] and statin drugs [19]. Compared to
diabetic patients initiated on metformin, those initiated on
sulphonylureas were more likely to discontinue their treat-
ment and less likely to initiate a second course of treatment after
discontinuation.
Although patients discontinuing therapy may suffer from a
lack of exposure to appropriate OAD during the period they are
off therapy, this result suggests that soon after metformin or
sulfonylurea treatment initiation, there are opportunities to
encourage and support better patient persistence with therapy
known to enhance microvascular [4,20] and perhaps macrovas-
cular [21] protection.
The erratic OAD treatment behaviors we have observed
potentially reduce treatment efﬁcacy and may lead to increased
diabetes complications. Further studies are required that relate
lack of OAD treatment continuity to health outcomes and costs.
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